Vertex Pharmaceuticals VRTX Finance Lease Right Of Use Asset Amortization
Finance Lease Right Of Use Asset Amortization at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAssetAmortization.
The official record: Vertex Pharmaceuticals’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's finance lease right of use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's finance lease right of use asset amortization?
- Vertex Pharmaceuticals (VRTX) reported finance lease right of use asset amortization of $1.8M in Q4 2025.
- How has Vertex Pharmaceuticals's finance lease right of use asset amortization changed year-over-year?
- Vertex Pharmaceuticals's finance lease right of use asset amortization decreased by 76.7% year-over-year, from $7.73M to $1.8M.
- What is the long-term trend for Vertex Pharmaceuticals's finance lease right of use asset amortization?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's finance lease right of use asset amortization has grown at a -58.9% compound annual growth rate (CAGR), from $42.7M to $7.2M.